NovoCure (NVCR) Change in Acquisitions & Divestments (2014 - 2026)

NovoCure (NVCR) has reported Change in Acquisitions & Divestments for 13 consecutive years, with $95.0 million the latest figure, recorded in Q2 2026.

• Quarterly Change in Acquisitions & Divestments fell 77.38% year-over-year to $95.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $950.0 million (up 5.56% YoY) and the FY2025 annual result came in at $1.3 billion, up 65.17% from the prior year.
• Change in Acquisitions & Divestments slipped to $95.0 million in Q2 2026 per NVCR's latest filing, from $110.0 million in the prior quarter.
• Over the last five years, Change in Acquisitions & Divestments for NVCR reached as high as $560.0 million in Q4 2025 and fell as low as $95.0 million in Q2 2026.
• A 5-year average of $259.0 million and a median of $266.8 million in 2023 frame the typical range for Change in Acquisitions & Divestments.
• Annual changes were most pronounced in 2025 — Change in Acquisitions & Divestments jumped 229.41% — and 2026, when it plunged 77.38%.
• Year by year, Change in Acquisitions & Divestments stood at $104.5 million in 2022, then surged by 185.62% to $298.5 million in 2023, then plunged by 43.06% to $170.0 million in 2024, then soared by 229.41% to $560.0 million in 2025, then tumbled by 83.04% to $95.0 million in 2026.
• According to Business Quant data, Change in Acquisitions & Divestments over the past three periods registered $95.0 million, $110.0 million, and $560.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.